2 results
Approved WMOCompleted
Primary objective- To assess the tolerability and safety of SAR444336 after single and repeated ascending subcutaneous doses Secondary objectives- To assess the PK parameters of SAR444336 after single ascending subcutaneous doses (Part 1)- To assess…
Approved WMOPending
Main Phase:To demonstrate the superiority of medium-dose BDP/FF/GB pMDI compared to high-dose BDP/FF pMDI in terms of the proportion of subjects exhibiting on average NPAL over 26 weeks of treatment in the study sub-population with PAL at screening…